Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Inventory (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Inventory for 5 consecutive years, with $54.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 108.22% year-over-year to $54.9 million, compared with a TTM value of $54.9 million through Dec 2025, up 108.22%, and an annual FY2025 reading of $54.9 million, up 108.22% over the prior year.
  • Inventory was $54.9 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $41.4 million in the prior quarter.
  • Across five years, Inventory topped out at $54.9 million in Q4 2025 and bottomed at $2.2 million in Q1 2021.
  • Average Inventory over 5 years is $23.8 million, with a median of $23.7 million recorded in 2023.
  • The sharpest move saw Inventory skyrocketed 504.07% in 2022, then dropped 19.1% in 2025.
  • Year by year, Inventory stood at $3.7 million in 2021, then skyrocketed by 487.73% to $21.6 million in 2022, then surged by 44.09% to $31.1 million in 2023, then decreased by 15.29% to $26.4 million in 2024, then surged by 108.22% to $54.9 million in 2025.
  • Business Quant data shows Inventory for KNSA at $54.9 million in Q4 2025, $41.4 million in Q3 2025, and $48.2 million in Q2 2025.